SkyePharma due $1M from Somnus as Ph I SKP-1041 trial completes
UK firm SkyePharma and its partner USA-based Somnus Therapeutics have completed the first Phase I trial of their controlled-release sleep maintenance product, SKP-1041. Under the terms of the deal between the firms, a $1.0 million milestone payment is now payable to the former.
SKP-1041 is a new formulation of zaleplon, a non-benzodiazepine hypnotic agent, which utilizes SkyePharma's proprietary Geoclock technology for controlled release. The formulation is designed to treat people who have difficulty maintaining sleep but not sleep onset, and is intended to prevent middle-of-the-night awakening while avoiding daytime drowsiness.
In June 2007, SkyePharma entered into an exclusive agreement with Somnus for the worldwide development and commercialization of SKP-1041. Under the terms of the deal, SkyePharma will formulate and manufacture the product and Somnus will develop and commercialize it.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze